Lenalidomideas a Second-line Therapy Achieves Long-term Remission in Elderly Patients with Relapsed/Refractory Multicentric Castleman's Disease：a Report of Two Cases and Literature Review

Abstract

No standard therapy is recommended for elderly multicentric Castleman's disease (MCD) patients who failed to the first-line treatment or relapsed. Lenalidomide has been reported to be effective for relapsed/refractory MCD in foreign countries, but its effect on this disease has been rarely reported in China. We reported two elderly patients with relapsed/refractory MCD presented with long-term remission after second-line treatment with lenalidomide, and reviewed relevant literature, then suggested that lenalidomide showed encouraging efficacy in patients with MCD, which may be an attractive alternative for relapsed/refractory MCD. Elderly patients with MCD may be more likely to benefit from lenalidomide-based treatment because of the poor general condition and various complications.

Keywords

• |multicentric castleman's disease|aged|lenalidomide|recurrence|refractory diseases